Sarcoma Survivorship Follow-Up Questions

Soft tissue sarcoma is uncommon. The US totals for 2026 are American Cancer Society projections: 13,910 new cases and 5,400 deaths. NCI's own SEER measurements sit alongside them. The rate of new cases was 3.5 per 100,000 people a year for 2019 to 2023. The death rate was 1.3 per 100,000 for 2020 to 2024.

Rarity shapes follow-up. There is no single national schedule of scans. What PDQ does provide is data on where relapses happened and how they were caught, which is more useful than a calendar.

PDQ summarizes a review of 174 patients with limb sarcoma. They were followed at one center from 2003 to 2009. PDQ grades it Level of evidence C2. That means a look back, not a trial. The numbers are still worth carrying into a visit.

• 82 patients, or 47%, relapsed.
• 26 had an isolated local recurrence. Another 5 had local return plus lung spread at the same time.
• Of those 31 local recurrences, 30 were picked up by clinical examination. MRI found exactly one.
• 28 patients, or 16%, developed lung metastases only. Chest x-ray found 19 of them, CT found 3, and 11 were found clinically.
• Of those lung metastases, 9 could be removed by surgery, and 7 of those 9 were free of disease afterward.
• 23 patients developed spread outside the lungs.

Two conclusions follow directly. Hands and eyes, not machines, found nearly every local return at the scar. And chest imaging earned its place, because lung spread is what imaging actually caught.

PDQ is candid about the limit: the effect of finding metastases early on survival or quality of life is unknown.

In that same review, more than 80% of relapses occurred within the first 2 years of follow-up. Later recurrences did happen.

PDQ names two histologies where late return is a known pattern: synovial sarcoma and alveolar soft-part sarcoma, where recurrences more than 5 years from diagnosis are seen. Knowing which histology a pathology report named changes how long watching matters.

PDQ adds that when recurrence is suspected, PET and CT imaging may be more sensitive than contrast-enhanced CT alone.

Most extremity sarcoma is treated without amputation. PDQ reports a study of 769 patients with high-grade limb sarcoma who had limb-sparing surgery. After a mean 45 months, there were 95 local recurrences. Local recurrence-free survival was 83.2% at 5 years and 75.9% at 10 years.

Radiation timing changed the shape of the curve. Radiation before surgery gave the best 5-year figure, 90.0%. Radiation after surgery gave better control by 10 years, 78.3%. Revision surgery was most common after radiation given first, at 9.0%. Surgery alone came next at 5.5%. Radiation given after came last at 4.4%. PDQ notes that gap was not statistically significant, with a P value of .085.

PDQ describes a smaller group treated with surgery alone. These are low-grade tumors of the limb or the surface of the trunk. They are 5 cm or smaller, with clean margins under the microscope. Long-term local control there runs about 90%.

PDQ also reports a comparison of 92 amputations against 557 limb-sparing procedures among 649 patients. Amputation gave significantly better local control. It gave no survival benefit.

PDQ's sarcoma summary names doxorubicin and ifosfamide across its chemo sections. Their FDA labels carry the long-term warnings.

The doxorubicin label carries a boxed warning for cardiomyopathy. That means damage to the heart muscle. The label says risk is proportional to total lifetime exposure. It puts rates at 1% to 20% for total doses of 300 mg/m² to 500 mg/m², given every 3 weeks. The label tells clinicians to measure left ventricular ejection fraction, a gauge of the heart's pumping. It says to do so before treatment, regularly during it, and after it. That "after" is the survivorship part. It makes the total lifetime dose a number worth having in writing.

The same boxed warning covers second cancers. It says two blood cancers occur at higher rates after anthracyclines, the drug family doxorubicin belongs to. Those are acute myelogenous leukemia and myelodysplastic syndrome.

The ifosfamide label has its own boxed warning. It covers four things. Low blood counts. Encephalopathy, meaning brain effects. Kidney toxicity that can end in kidney failure. And hemorrhagic cystitis, meaning bleeding from an inflamed bladder lining. The label directs at least 2 liters of fluid a day. It also directs mesna, a drug given to protect the bladder. PDQ names mesna in its own sarcoma regimens.

PDQ lists previous radiation therapy among the established risk factors for soft tissue sarcoma. That is the basis for watching a treated field long term.

It lists chronic lymphedema as a risk factor too, and only for lymphangiosarcoma. That is a different claim from lymphedema being a late effect of treatment. This summary does not describe it that way.

PDQ also names inherited syndromes that raise sarcoma risk. Li-Fraumeni syndrome comes from a TP53 change. Neurofibromatosis type 1 comes from an NF1 change. Gardner syndrome comes from an APC change. Gorlin syndrome comes from a PTCH1 change. In those families, follow-up is a lifelong question, not a five-year one.

Some things survivors are told are not in this summary at all. It gives no scan interval. It gives no fracture risk figure after radiation. It gives no expected lifespan for reconstruction hardware. So where a number is wanted, the fair move is to ask which guideline the team follows. PDQ does not supply one.

• What was my total cumulative doxorubicin dose in mg/m², and when is the next ejection fraction check?
• Did I receive ifosfamide, and does kidney function need long-term watching?
• What histology did my pathology report name, and is it one with late recurrences?
• Given that clinical exam found 30 of 31 local recurrences in PDQ's cited series, what exactly should be examined, and by whom?
• What chest imaging schedule is planned, and what guideline is it drawn from?

Follow-up visits are spaced out, so some things should not wait for the next one.

• Call 911 or go to an emergency department if you have chest pain, sudden breathlessness, or breathlessness lying flat with swollen ankles, or if you faint. Doxorubicin can damage heart muscle, and those are the signs that need checking straight away. Do the same for a bone that breaks after a minor knock, or for back pain with new leg weakness or loss of bladder or bowel control.
• Call your care team the same day if you see blood in your urine or passing urine burns, which can follow ifosfamide, or if you notice bruising or bleeding gums.
• An unexplained fever while chemotherapy is still running is not a same-day item. CDC treats it as a medical emergency, so ring the team at once whatever the hour, and use an emergency department if they cannot be reached.
• Call your care team within a day or two if you feel a new lump or firmness at your old surgical scar, or an old ache there changes. In the series PDQ cites, examination rather than scanning found nearly every local recurrence, so what you feel between visits matters.

The disease itself is described in sarcoma. What happens if it returns is covered in sarcoma recurrence. Broader life-after-treatment ground is in survivorship.

• NCI PDQ: soft tissue sarcoma, HP version
• NCI: drugs for soft tissue sarcoma
• American Cancer Society: Cancer Facts & Figures
• DailyMed: doxorubicin label
• DailyMed: IFEX label